References
- Borg, G., E. Allander, B. Lund, E. Berg, U. Brodin, H. Pettersson, and L. Trang. 1988. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. J. Rheumatol. 15, 1747-1754.
- Chen, X. L., G. Dodd, S. Thomas, X. Zhang, M. A. Wasserman, B. H. Rovin, and C. Kunsch. 2006. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am. J. Physiol. Heart Circ. Physiol. 290, H1862-H1870. https://doi.org/10.1152/ajpheart.00651.2005
- Gandin, V., A. P. Fernandes, M. P. Rigobello, B. Dani, F. Sorrentino, F. Tisato, M. Bjornstedt, A. Bindoli, A. Sturaro, R. Rella, and C. Marzano. 2010. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol. 79, 90-101. https://doi.org/10.1016/j.bcp.2009.07.023
- Gromer, S., L. D. Arscott, C. H. Jr. Williams, R. H. Schirmer, and K. Becker. 1998. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. 273, 20096-20101. https://doi.org/10.1074/jbc.273.32.20096
- Innamorato, N. G., A. I. Rojo, A. J. García-Yague, M. Yamamoto, M. L. de Ceballos, and A. Cuadrado. 2008. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol. 181, 680-689. https://doi.org/10.4049/jimmunol.181.1.680
- Jeon, K. I., J. Y. Jeong, and D. M. Jue. 2000. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J. Immunol. 164, 5981-5989. https://doi.org/10.4049/jimmunol.164.11.5981
- Jeon, K. I., M. S. Byun, and D. M. Jue. 2003. Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp. Mol. Med. 35, 61-66. https://doi.org/10.1038/emm.2003.9
- Jeong, W. S., I. W. Kim, R. Hu, and A. N. Kong. 2004. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm. Res. 21, 661-670. https://doi.org/10.1023/B:PHAM.0000022413.43212.cf
- Jin, W., H. Wang, W. Yan, L. Xu, X. Wang, X. Zhao, X. Yang, G. Chen, and Y. Ji. 2008. Disruption of Nrf2 enhances upregulation of nuclear factor-kappaB activity, proinflammatory cytokines, and intercellular adhesion molecule-1 in the brain after traumatic brain injury. Mediators Inflamm. 2008, 1-7.
- Kang, M. I., A. Kobayashi, N. Wakabayashi, S. G. Kim, and M. Yamamoto. 2004. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proc. Natl. Acad. Sci. USA 101, 2046-2051. https://doi.org/10.1073/pnas.0308347100
- Kim, I. S., J. Y. Jin, I. H. Lee, and S. J. Park. 2004. Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Brit. J. Pharmacol. 142, 749-755. https://doi.org/10.1038/sj.bjp.0705708
- Kim, N. H., M. Y. Lee, S. J. Park, J. S. Choi, M. K. Oh, and I. S. Kim. 2007. Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 122, 607-614. https://doi.org/10.1111/j.1365-2567.2007.02679.x
- Kim, N. H., M. K. Oh, S. J. Park, and I. S. Kim. 2010. Auranofin, a gold(I)-containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation. J. Pharmacol. Sci. 113, 246-254. https://doi.org/10.1254/jphs.09330FP
- Kirino, Y., M. Takeno, S. Murakami, M. Kobayashi, H. Kobayashi, K. Miura, H. Ideguchi, S. Ohno, A. Ueda, and Y. Ishigatsubo. 2007. Tumor necrosis factor alpha acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes. Arthritis. Rheum. 56, 464-475. https://doi.org/10.1002/art.22370
- Kensler, T. W., N. Wakabayashi, and S. Biswal. 2007. Cell Survival Responses to Environmental Stresses via the Keap1-Nrf2-ARE Pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89-116. https://doi.org/10.1146/annurev.pharmtox.46.120604.141046
- Kobayashi, H., M. Takeno, T. Saito, Y. Takeda, Y. Kirino, K. Noyori, T. Hayashi, A. Ueda, and Y. Ishigatsubo. 2006. Regulatory role of heme oxygenase 1 in inflammation of rheumatoid arthritis. Arthritis. Rheum. 54, 1132-1142. https://doi.org/10.1002/art.21754
- Li, W., T. O. Khor, C. Xu, G. Shen, W. S. Jeong, S. Yu, and A. N. Kong. 2008. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem. Pharmacol. 76, 1485-1489. https://doi.org/10.1016/j.bcp.2008.07.017
- Lin, W., R. T. Wu, T. Wu, T. O. Khor, H. Wang, and A. N. Kong. 2008. Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem. Pharmacol. 76, 967-973. https://doi.org/10.1016/j.bcp.2008.07.036
- Nobili, S., E. Mini, I. Landini, C. Gabbiani, A. Casini, and L. Messori. 2010. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med. Res. Rev. 30, 550-580.
- Park, S. J. and I. S. Kim. 2005. The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br. J. Pharmacol. 146, 506-513. https://doi.org/10.1038/sj.bjp.0706360
- Park, S. J., M. Kim, N. H. Kim, M. K. Oh, J. K. Cho, J. Y. Jin, and I. S. Kim. 2008. Auranofin promotes retinoic acid- or dihydroxyvitamin D3-mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation. Br. J. Pharmacol. 154, 1196-1205. https://doi.org/10.1038/bjp.2008.197
- Rigobello, M. P., V. Gandin, A. Folda, A. K. Rundlof, A. P. Fernandes, A. Bindoli, C. Marzano, and M. Bjornstedt. 2009. Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift. Free Radic. Biol. Med. 47, 710-721. https://doi.org/10.1016/j.freeradbiomed.2009.05.027
- Thimmulappa, R. K., H. Lee, T. Rangasamy, S. P. Reddy, M. Yamamoto, T. W. Kensler, and S. Biswal. 2006. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J. Clin. Invest. 116, 984-995. https://doi.org/10.1172/JCI25790
- Tiekink, E. R. 2008. Anti-cancer potential of gold complexes. Inflammopharmacology 16, 138-142. https://doi.org/10.1007/s10787-007-0018-5
- Yamada, R., H. Sano, T. Hla, A. Hashiramoto, W. Fukui, S. Miyazaki, M. Kohno, Y. Tsubouchi, Y. Kusaka, and M. Kondo. 1999. Auranofin inhibits interleukin-1beta-induced transcript of cyclooxygenase-2 on cultured human synoviocytes. Eur. J. Pharmacol. 385, 71-79. https://doi.org/10.1016/S0014-2999(99)00707-4
- Youn, H. S., J. Y. Lee, S. I. Saitoh, K. Miyake, and D. H. Hwang. 2006. Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. Biochem. Biophys. Res. Commun. 350, 866-871. https://doi.org/10.1016/j.bbrc.2006.09.097